American Gene Technologies International

American Gene Technologies (AGT) is a clinical-stage biotechnology company based in Rockville, Maryland, specializing in the development of gene therapies for infectious diseases, monogenic disorders, and cancer. The company utilizes a proprietary lentiviral vector platform to create precision genetic medicines designed to repair or replace defective genes. AGT's lead candidate, AGT103-T, is an autologous cell therapy that has successfully completed a Phase 1 clinical trial aimed at providing a functional cure for HIV. In 2023, the company launched Addimmune, a dedicated entity to focus exclusively on the commercialization of its HIV cure program. Beyond HIV, AGT is advancing a pipeline that includes treatments for Phenylketonuria (PKU) and various solid tumors.